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INTRODUCTION
Expression of the PML-RAR fusion protein -originated by the t (15;17) chromosomal translocation-is associated with >95% cases of Acute Promyelocytic Leukemia (APL) 1 . APL blasts are sensitive to the differentiative action of pharmacological concentrations of Retinoic Acid (RA), that, in association with standard chemotherapy, has become the elective treatment for these patients, leading to long-term remissions 2, 3 .
Studies conducted in cell lines showed that PML-RAR is able to block differentiation upon several differentiating stimuli, and that this effect is reverted by RA treatment 4 . These results suggested that PML-RAR is responsible for both the pathogenesis of the disease, and for its RA sensitivity. In vivo studies using transgenic chicken and mice confirmed this hypothesis [5] [6] [7] [8] [9] [10] [11] [12] [13] . Expression of PML-RAR in mice under different myeloid-specific promoters gave two kind of results: a) in the case of promoters for genes expressed during early myeloidpromyelocytic stages of differentiation, such as cathepsin-G and MRP8, PML-RAR induced slight alterations in myelopoiesis ("pre-leukemic syndrome") in 100% of mice, and an APL-like leukemia at low penetrancy (15-20%) and long latency (6-18 months) 6, [8] [9] [10] ; b) in the case of promoters for late stages of myeloid differentiation, such as CD11b, expression of PML-RAR provoked a modest impairment in hematopoiesis, without induction of an overt leukemic syndrome 7 .
These results underscore the relevance of the proper targeting of PML-RAR expression and suggest a "two-hit" model, where expression of the fusion protein is not sufficient for leukemogenesis, but creates a cellular environment favorable for the accumulation of additional genetic lesions 12, 13 .
We have developed an alternative strategy to express PML-RAR in the hematopoietic compartment, by retroviral-based transduction of murine hematopoietic progenitors and subsequent reinoculation of syngeneic mice. Our results confirm and extend the observations obtained by the conventional transgenic models, and offer a new, more versatile model system to study APL pathogenesis.
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METHODS

Plasmids. The plasmids PINCO (empty vector, GFP expressing), PINCO-RAR,
and PINCO-PML-RAR (expressing GFP and PML-RAR) have been described previously 14, 15 .
Purification of lin-cells. Lin -cells were purified from the bone marrow of eightten weeks old 129SvEv mice. After centrifugation through a Ficoll gradient, mononucleate cells were enriched for progenitors by depletion of cells presenting myeloid, erythroid, and lymphoid differentiation markers using commercially available reagents (StemCell Technologies, Canada). 
Differentiation and survival assays.
To analyze differentiation in vitro, sorted cells or uninfected control lin-cells were plated (5,000 cells/plate) in methylcellulose medium containing fetal bovine serum and the following cytokines: IL3 (20ng/ml), IL6 (20ng/ml), SCF (100ng/ml), G-CSF (60ng/ml), and GM-CSF (20ng/ml). 7-10 days after plating, cells were harvested and characterized by analysis of surface myeloid markers (MAC1 and GR1). For in vivo studies, cells from peripheral blood, bone marrow or spleen of healthy and leukemic mice were analyzed for the presence of surface progenitor markers (C-KIT, CD34 and SCA1) and myeloid markers ( GR1 and MAC1). Murine antibodies for C-KIT, CD34, SCA1, GR1, MAC1 and their matched isotype controls were purchased from PharMingen and used according to the manufacturer's instruction. Cells were analyzed by a Becton Dickinson FACScan, using CELL QUEST software.
In survival assays in vitro, cells were plated in methylcellulose medium as described above. After 10 days, pooled colonies were re-seeded (10,000 cells/plate) in semisolid medium. The assay was repeated until no colonies developed in control plates (usually, 2-3 platings), due to terminal differentiation of the cells 16 .
Repopulation of lethally irradiated recipients. 129 SvEv wt mice were lethally irradiated (9 Gy) and re-injected intravenously (i.v.) with 300,000 sorted cells plus 500.000 spleen cells (obtained from an untreated mouse); after 7 days, mice were re-injected i.v. with 500.000 spleen cells. Mice re-injected with spleen cells only survived slightly longer than untreated, irradiated mice (approx. 4 weeks vs 1-2 weeks), but eventually they all died due to impaired hematopoiesis.
The animals were checked periodically for clinical signs of disease, and for presence of blast cells by May-Grünwald Giemsa staining of blood smears.
Morphologic analysis. Mice were euthanized by CO 2 inhalation, and underwent necropsy. Main organs were fixed in 10% buffered formalin and processed for histopathological examination. Samples were embedded in paraffin, sectioned at 4µm and stained with Hematoxylin-Eosin. Blood smears, bone marrow smears and spleen cells imprints were stained with May-Grunwald-Giemsa and Sudan
Black-B.
DNA, RNA, and protein analysis. DNA-PCR and RT-PCR from colonies derived from methylcellulose plating, or from leukemic animals, were performed according to standard techniques, using primers specific for the human PML-RAR cDNA 17 . As a routinary control for DNA quality of all of our genomic samples, we have used primers to amplify a genomic sub-region of the murine p21 gene. In all of the samples shown in the figures, that test resulted positive.
For Southern blot analysis, genomic DNAs from spleen, liver or bone marrow of leukemic mice (primary or secondary recipients) were digested with HindIII, run on an agarose gel, and then blotted to nylon membranes (Amersham). The filters were hybridized using an HindIII-EcoRI 3 kb fragment containing the entire PML-RAR cDNA. 8 primary leukemic samples, and 12 secondary/tertiary leukemic samples were analyzed in this study: four representative primary cases/two secondary cases are shown in figure 6 . For protein analysis, immunoblotting and immunofluorescence experiments were performed using antibodies specific for the human and mouse PML 18 . Immunoprecipitations were performed using antibodies against human PML, followed by analysis of the immunoprecipitates by immunoblotting using anti-RAR antibodies.
FISH analysis. Metaphase spleen cells were obtained from leukemic mice as described 19 . PINCO PML/RAR was labelled as described 20 . FISH analysis was performed using Applied Spectral Imaging (ASI, Carlsbad, CA) and the software SKY View 1.6.1. Absence/presence of blast cells, differentiation and recovery were evaluated on peripheral blood smears stained with May-Grunwald-Giemsa or Sudan Black B.
All procedures involving animals were done in accordance with national and international laws and policies. Uninfected or GFP+ lin-cells were plated in methylcellulose in the presence of cytokines. Colonies were pooled, and analyzed for the expression of the myeloid differentiation markers MAC1 and GR1. PML-RAR expressing cells were impaired in their capacity to differentiate, unless pharmacological concentrations of Retinoic Acid (RA) were added to the medium ( Figure 1B) . As previously reported, lower doses of RA had no or marginal effect 15, 16 (data not shown).
RESULTS
Ectopic
Evaluation of proliferative potential by serial replating of methylcellulose colonies revealed the ability of PML-RAR-expressing cells to re-form colonies, in contrast to control or RA-treated PML-RAR cells, which lost the capacity to grow in methylcellulose after a few platings, due to terminal differentiation ( Figure 1C ).
Morphologically, PML-RAR colonies consisted of small clusters ( Figure 1D ) of immature, promyelocyte-like cells ( Figure 1E ). During these experiments, we noticed that GFP expression decreased dramatically in PML-RAR, but not in control, cells. This might be due to silencing of the CMV promoter by the fusion protein, since this promoter contains binding sites for PML-RAR 21 : we are currently evaluating the molecular mechanisms responsible for this phenomenon.
We picked twenty individual colonies after methylcellulose plating, and confirmed by DNA and RNA analysis that all of the colonies from PML-RAR derived plates originated from cells infected with the PML-RAR retroviral construct (see Figure   1F for representative DNA-PCR data from six colonies).
The capacity of PML-RAR to block myeloid differentiation (at the promyelocytic stage), and to prolong cell survival in a RA-reversible fashion indicates that our model system recapitulates the biological properties of the human disease in vitro, thus prompting us to examine the effect of fusion protein expression in vivo.
PML-RAR expressing cells cause an APL -like disease in mice.
Immediately after sorting, GFP+ cells from control, PML-RAR or RAR-transduced cells were reinoculated into lethally irradiated recipient mice. More than 95% of the mice reconstituted with control, GFP-expressing cells survived for more than 6 months, whereas the non-reinoculated mice died within 1-2 weeks after irradiation (Table 1 and Figure 2 ). Mice reconstituted with lin-transduced with the empty vector showed a variable (from 10 to more than 80%) degree of GFP+ cells in the peripheral blood or bone marrow (not shown). We did not observe differences in the expression of myeloid, lymphoid, and erythroid differentiation markers in the GFP+ and GFP- Table 1 ). The calculated, two-sided P values (Fischer's exact test) were in all cases extremely significant (P < 0,0001 for PML-RAR vs control or empty vector; P < 0,0005 for PML-RAR vs RAR -see Table 1 for further details). Massive splenomegaly and hepatomegaly were present in all PML-RAR mice, with frequent lymphoadenomegaly (figure 5A and data not shown).
Histopathological examination showed leukemic cells diffusely invading the bone marrow ( Figure 3B ), the splenic red pulp, and the liver (not shown and Figure   5C ). Moderate to severe infiltration of leukemic cells was also frequently detectable in the lymphonodes, lungs, meninges, and less frequently in the kidneys. Cytologically, the disease was characterized by extensive prevalence of promyelocytes, and, to a lesser degree, metamyelocytes ( Figure 3C and 5E). In human APL, treatment with RA alone results in disease remission and subsequent relapse in virtually all patients 2, 3 . Likewise, suspension of RA treatment in the leukemic mice resulted in relapse in 100% of mice ( Figure 5B ).
Taken together, these results show that our mouse model faithfully reproduce the main biological and clinical features of human APL. a mono-, or oligo-clonal disease, that follows a pre-leukemic 
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state.
To evaluate the polyclonal or clonal origin of the mouse APL leukemias, we performed Southern blotting analysis of integrated proviruses. A polyclonal origin is consistent with the capacity of PML-RAR to directly transform target cells, while a monoclonal, or oligoclonal origin suggests a two-hit model of leukemogenesis, e.g. the requirement for additional genetic lesions 6, 13 . Genomic DNAs from spleen/bone marrow of four primary and two secondary leukemic mice were digested with the HindIII restriction enzyme (which cuts once in the integrated retroviral sequence, allowing recognition of individual integration events) and hybridized with a probe representative of the human PML-RAR cDNA. Figure 6 . APL is a mono-, or oligo-clonal disease. Genomic DNA was prepared from leukemic mice (L1-L4, lanes 1, 3, 5 and 6), or from mice with secondary leukemias derived from reinjection of spleen cells from L1-L2 mice (lanes 2, 4). Samples were digested with HindIII, and then analyzed by Southern blot assay using the PML-RAR cDNA as a probe. (B) FISH analysis (using the proviral sequence as a probe) of metaphase-enriched nuclei of cells derived from the case "L1". Arrowheads highlight the hybridization signals.
As observed in Figure 6A , all the primary leukemias showed a discrete number of hybridizing DNA fragments (2 to 4 in the cases shown). Primary and secondary leukemia samples revealed the same patterns of multiple hybridizing fragments (compare lanes 1 and 2, 3 and 4 in Figure 6A ). The presence of multiple hybridizing fragments can be the consequence of a single, yet complex, integration site, or of several integration sites in the leukemia initiating cell. To clarify this issue, we performed FISH analysis of leukemic metaphases using a probe encompassing the entire integrated sequence. Strikingly, in the case where two hybridizing fragments were observed, we detected two hybridizing regions, confirming the monoclonality of the leukemia, and the presence of two integration events ( Figure 6B ). Overall, these results support the mono-, or oligoclonal origin of the leukemic blasts, and the hypothesis that leukemia arose from one PML-RAR expressing cell undergoing additional genetic lesions.
We next investigated whether expression of PML-RAR is sufficient to induce a detectable phenotype, prior to the onset of an overt leukemia. In the transgenic mice carrying PML-RAR under the MRP-8 or cathepsin-G promoters, a mild defect in myeloid maturation was consistently seen in 100% of the mice, defined as a "pre-leukemic" state and characterized by a slight decrease of MAC1 or GR1 expression in the whole bone marrow 6, 13 . We did not, however, detect a These results suggest that -as in the transgenic mice-a "pre-leukemic" state may be observed in our experimental system, and corresponds to an alteration in the differentiation potential induced by the fusion protein in hematopoietic progenitors.
DISCUSSION
We have presented here a novel model system to study APL in mice , based on Point-mutations harbored by the provirus, however, modified the intra-cellular localization of PML-RAR, resulting in a disease not resembling human APL, and that was not sensitive to RA treatment 5 . In transgenic mice, PML-RAR was expressed under the control of myeloid specific promoters (MRP-8 or cathepsin G) [6] [7] [8] [9] [10] . In those systems, RAR carrying a mutation in its ligand binding domain was shown to be non-leukemogenic: the results presented here, using wild-type RAR, further demonstrate that over-expression of RAR does not induce leukemias 10 . In the previous studies, PML-RAR leukemias developed after long latency (6-18 months) and at low penetrance (10-30%). Simultaneous expression of the product of the reciprocal translocation (RAR-PML) was shown to increase frequency (to about 50%), without affecting the latency of the disease 24 . In our experiments, instead, induction of a leukemic phenotype was observed in >80% of the mice upon expression of PML-RAR, with decreased latency (median time of about 4 months) compared to the transgenic models. This discrepancy is not due to different levels of PML-RAR, since direct comparison of fusion protein expression revealed comparable levels among the different model systems (catepsin-G, MRP8 transgenics and ours; Figure 4B ). The long latency and low frequency of leukemias in the transgenic mice suggested a "two-hit" model, that is consistent with the clonal origin of leukemias in our model system. Differences among the various model systems might, instead, be due to different targeting of the PML-RAR cDNA 13 . Expression of PML-RAR in transgenic mice strictly depend on the promoter used, as shown by the failure of late myeloid-stage specific promoters (CD11b) to provoke leukemias 7 The possibility to study the same cell populations in vitro and in vivo is, indeed, one of the greatest advantages of our experimental system. In vitro, we have shown that PML-RAR blocks differentiation and extend survival of lin-cells: by structure-function analysis, it will be possible to dissect these two phenotypes, and validate immediately the results in vivo.
Finally, RA sensitivity of primary and secondary leukemias, as well as of the preleukemic state observed in vitro, shows that this system is also available for pharmacological studies. Aberrant recruitment of histone deacetylases (HDACs) is considered critical for the leukemogenic potential of PML-RAR and other AML fusion proteins, and treatment with HDAC inhibitors is able to induce differentiation in vitro 26 . Treatment of the leukemic mice with HDACi, or other pharmacologically active compounds, may lead to new proposals for the therapy of APL, and possibly other types of cancers.
